Zoldonat (Zoledronic Acid) 4 mg โ 1 Vial
Zoldonat is a potent bisphosphonate injection used in oncology care. Active ingredient: Zoledronic Acid (4 mg).
Manufacturer: Natco Pharma (India). Generic equivalent of Zometa.
Mechanism of Action:
It inhibits osteoclast activity, effectively stopping the breakdown of bone tissue. In cancer patients with bone metastases, Zoldonat strengthens the bones, reduces pain, and prevents serious skeletal complications like fractures.
โ Key Benefit: Reduces the risk of Skeletal Related Events (SREs) in patients with advanced malignancies involving bone.
Indicated for:
- Bone Metastases: From solid tumors (breast cancer, prostate cancer, lung cancer, etc.) and Multiple Myeloma.
- Hypercalcemia of Malignancy (HCM): Life-threatening high calcium levels induced by cancer.
Form: Lyophilized powder (must be reconstituted and diluted).
Administration:
- ๐ Intravenous infusion over no less than 15 minutes. Administered every 3-4 weeks.
- Patient must be well-hydrated prior to infusion.
โ ๏ธ CRITICAL WARNINGS:
- Dental Health: Complete all invasive dental work BEFORE starting therapy. Risk of Osteonecrosis of the Jaw (ONJ).
- Supplements: Patients usually take oral Calcium (500 mg) and Vitamin D (400 IU) daily, unless treating hypercalcemia.
- Severe renal impairment (Creatinine clearance < 30 mL/min).
- Pregnancy and breastfeeding.
- Hypocalcemia (low calcium levels).
"Post-Dose Syndrome":
Fever, chills, bone pain, and muscle aches are very common within the first 3 days of administration. This is temporary and can be managed with Paracetamol/Ibuprofen.
Serious Risks:
- Renal toxicity (Serum creatinine monitoring is mandatory before each dose).
- Osteonecrosis of the Jaw (ONJ).
What Customers Say
No reviews yet
Your review can be the first!